Financial Results Approval
The Board of Directors approved the Audited Financial Results for the Quarter and Year ended 31st March, 2026 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.
Key Financial Figures (INR in Lakhs)
For Year Ended 31st March, 2026 (Audited):
- Revenue from Operations: ₹5,363.40
- Other Income: ₹922.23
- Total Income: ₹6,285.63
- Total Expenses: ₹1,782.77
- Profit before exceptional items and tax: ₹5,339.20
- Exceptional Items: ₹946.44
- Profit before tax: ₹946.44
- Current Tax: ₹257.00
- Deferred Tax: ₹(4.27)
- Net Profit after tax: ₹693.71
- Other Comprehensive Income: ₹(7.29)
- Total Comprehensive Income: ₹686.41
- Basic EPS: ₹6.70
- Diluted EPS: ₹6.70
For Quarter Ended 31st March, 2026 (Audited):
- Revenue from Operations: ₹1,619.53
- Other Income: ₹295.58
- Total Income: ₹1,915.11
- Total Expenses: ₹396.14
- Profit before exceptional items and tax: ₹1,745.42
- Exceptional Items: ₹169.70
- Profit before tax: ₹169.70
- Current Tax: ₹54.00
- Deferred Tax: ₹0.34
- Net Profit after tax: ₹115.35
- Other Comprehensive Income: ₹(1.29)
- Total Comprehensive Income: ₹114.06
- Basic EPS: ₹1.05
- Diluted EPS: ₹1.05
Dividend Recommendation
The Board recommended a final dividend @ 35% on the fully paid-up Equity Share Capital of the Company i.e., ₹3.50 per each fully paid equity share, subject to the approval of members in the ensuing Annual General Meeting.
Auditor Appointments
- Re-appointment of Mr. Sativada Venkat Rao, Cost Accountant, Hyderabad (Registration No. 100340) as cost Auditor for Financial Year 2026-27
- Re-appointment of M/S K Srinivas & Associates, Chartered Accountants (FRN: 022462S) as Internal Auditor for Financial Year 2026-27
Auditor Report
The Statutory Auditor, M/S P.S.N. Ravishanker & Associates, issued an unmodified opinion on the Audited Financial Results for the Quarter and Year ended 31st March, 2026.
Operational Highlights
- The Company operates exclusively in one reportable business segment: APIs (Active Pharmaceutical Ingredients)
- Export sales for Quarter ended March 31, 2026: ₹1,450.78 Lakhs
- Export sales for Year ended March 31, 2026: ₹4,841.33 Lakhs
- No liability/provision required under New Labour Codes as impact assessed to be NIL
Meeting Details
The Board Meeting commenced at 16:30 P.M and concluded at 20:15 P.M on 28th May, 2026.
Additional Information
- Paid up Equity Share Capital: ₹1,024.53 Lakhs (Face value of ₹10 per share)
- Other Equity: ₹13,022.50 Lakhs
- Results available at company's website www.tycheindustries.net and BSE website www.bseindia.com
Balance Sheet Highlights (as of 31st March, 2026)
- Total Assets: ₹14,804.32 Lakhs
- Total Equity: ₹14,047.03 Lakhs
- Non-Current Liabilities: ₹101.49 Lakhs
- Current Liabilities: ₹655.80 Lakhs
Cash Flow Statement (Year Ended 31st March, 2026)
- Net Cash Flow from Operating Activities: ₹56.94 Lakhs
- Net Cash Flow used in Investing Activities: ₹(1,119.39) Lakhs
- Net Cash Flow used in Financing Activities: ₹(307.22) Lakhs
- Net Decrease in Cash and Cash equivalents: ₹(916.74) Lakhs